Register for OBR daily


To find out more about a company click on the company name to see a brief profile.

OBR Finance Top 5 Winners

CERU $9.98 0.4000 +4.18%
CYTK $7.12 0.2700 +3.94%
NLNK $48.93 1.5700 +3.32%
LOXO $13.41 0.4000 +3.07%
CVM $1.06 0.0300 +2.91%

Quotes Are Updated Every 20 Minutes. Companies with a Market Cap of less than $50M are not included.

OBR Finance Top 5 Losers

CBMG $39.60 -3.4300 -7.97%
CALA $15.88 -1.2500 -7.30%
KITE $57.75 -4.5200 -7.26%
RDUS $41.84 -2.7500 -6.17%
CTIC $1.80 -0.1100 -5.76%

Quotes Are Updated Every 20 Minutes. Companies with a Market Cap of less than $50M are not included.

Archived News Headlines

We have been archiving all OBR daily news stories since March 2008. Use the box below to search our archives for specific articles and content.

Please note: we do not "host" news articles on our website. When a media source removes an article from their website the link becomes inactive, and you will only be able to see the date, title, first sentence and media source that published the article.

<< First | < Prev | 11 | 12 | 13 | 14 | 15 | 16 | 17 | 18 | 19 | 20 | Next > | Last >>

How Much Is One Cancer Drug Worth?

(Wall Street Journal/Pharmalot blog) Mar 5, 2015 - A look inside the AbbVie deal to buy Pharmacyclics and its Imbruvica medication.
read article (paid subscription required) 

Veracyte Announces New Data That Inform Optimal Use of Molecular Testing in Preoperative Thyroid Nodule Assessment

(Yahoo! Finance) Mar 6, 2015 - Veracyte, Inc. today announced new data demonstrating that diagnostic tests that use increasing numbers of cancer-associated gene mutations to evaluate thyroid nodules can dramatically reduce the specificity of test results, leading to an increase in "false positives," in which benign nodules are erroneously diagnosed as cancerous.
read article 

AVEO Oncology Announces Presentation of Phase 2 Study Analysis Showing Longer PFS With Tivozanib Compared to Bevacizumab in Low Serum NRP-1 Patients With Advanced CRC

(MarketWatch) Mar 6, 2015 - AVEO Oncology today announced the presentation of final results, including a predefined biomarker analysis, from the BATON- (Biomarker Assessment of Tivozanib in ONcology) CRC study, a randomized Phase 2 clinical trial of modified FOLFOX6 combined with tivozanib or bevacizumab in metastatic colorectal cancer (CRC).
read article 

Lung Cancer Stem Cell Therapy to Be Trialled in UK

(The Guardian [UK]) Mar 6, 2015 - British patients will be the first in the world to receive a pioneering cell therapy that scientists hope will transform the treatment of lung cancer.
read article 

Prenatal Blood Tests Detect Cancer Signal in Some Women

(Reuters) Mar 5, 2015 - A new genetic test that sequences the blood of pregnant women for signs of diseases such as Down Syndrome in their fetuses are turning up unexpected results: a diagnosis of cancer in the mother.
read article 

Unregulated Web Marketing of Genetic Tests For Personalized Cancer Care Raises Concerns in New Study

(Dana-Farber) Mar 5, 2015 - Websites that market personalized cancer care services often overemphasize their purported benefits and downplay their limitations, and many sites offer genetic tests whose value for guiding cancer treatment has not been shown to be clinically useful, according to a new study from Dana-Farber Cancer Institute.
read press release 

Researchers Track Trends For Oncotype DX Breast Cancer Recurrence Test Following Medicare Coverage

(GenomeWeb) Mar 5, 2015 - In JAMA Oncology, researchers from Duke University and elsewhere looked at the uptake and use of Genomic Health's Oncotype DX breast cancer recurrence assay in Medicare beneficiaries in the years following its coverage approval.
read article (free registration required) 

FDA Approves First Lower-Cost Biotech Drug

(ABC News/Associated Press) Mar 6, 2015 - Federal health officials have approved the first lower-cost copy of a biotech drug to reach the U.S. market, a long-awaited milestone that could generate billions in savings for insurers, doctors and patients.
read article 

AbbVie Wins Bidding War for Maker of Cancer Drug, Then Goes on Defensive

(New York Times) Mar 5, 2015 - The amount stunned Wall Street, pushed aside one of the giants of the pharmaceutical sector, Johnson & Johnson, and set off a debate about whether AbbVie had paid too much.
read article 

Nobel Laureate Harold Varmus Joins Weill Cornell Medical College to Advance Cancer Research

(Weill Cornell Medical College) Mar 5, 2015 - Dr. Harold Varmus, director of the National Cancer Institute (NCI) at the National Institutes of Health (NIH) and co-winner of the Nobel Prize, will join Weill Cornell Medical College's faculty as the Lewis Thomas University Professor of Medicine, effective April 1.
read press release 

Is Most of Our DNA Garbage?

(New York Times Magazine) Mar 5, 2015 - T. Ryan Gregory’s lab at the University of Guelph in Ontario is a sort of genomic menagerie, stocked with creatures, living and dead, waiting to have their DNA laid bare.
read article 

New Ebola Vaccine to Be Tested in Guinea

(Wall Street Journal) Mar 5, 2015 - An Ebola vaccine developed by Canada’s public health agency will go into late-stage human testing Saturday in Guinea, one of the three West African countries that has been hard hit by the disease, the World Health Organization said Thursday.
read article (paid subscription required) 

U.S. Supreme Court Split Over Obamacare Challenge

(Reuters) Mar 4, 2015 - The U.S. Supreme Court appeared sharply divided on ideological lines on Wednesday as it tackled a second major challenge to President Barack Obama's healthcare law, with Justice Anthony Kennedy emerging as a likely swing vote in a ruling.
read article 

ASCO Commends Dr. Harold Varmus’ Outstanding Leadership as NCI Director

(ASCO) Mar 5, 2015 - The American Society of Clinical Oncology (ASCO) is enormously grateful for the service and leadership of Harold Varmus, MD, as Director of the National Cancer Institute (NCI).
read press release 

COA Team on Capitol Hill Fighting for Community Oncology Issues

(COA) Mar 5, 2015 - Oncologists Drs. Dave Eagle, Michael Method, Mark Thompson and Jeff Vacirca were accompanied by practice leaders Tom Gallo, Brad Prechtl, and Barry Russo meeting with House leadership and others on oncology payment reform, prompt pay, sequester cut, SGR, 340B, and payment parity.
read article 

Eisai and Merck in Cancer Combo Deal

(PharmaTimes [UK]) Mar 5, 2015 - Eisai and Merck & Co have signed a deal to put various combinations of their cancer drugs through clinical testing.
read article 

AbbVie to Pay $21 Billion For Pharmacyclics, Maker of a Promising Cancer Drug

(New York Times/DealBook) March 4, 2015 - AbbVie announced late Wednesday that it had agreed to buy Pharmacyclics, maker of a cancer drug that some analysts predict will eventually become one of the best-selling treatments for the disease, for about $21 billion.
read article 

Bristol-Myers Hits 14-Year High as Cancer Drug’s Use Expands

(Bloomberg) Mar 4, 2015 - Bristol-Myers Squibb Co. shares hit a 14-year high after the company won expanded U.S. approval for its drug Opdivo to treat lung cancer, more than three months ahead of schedule.
read article 

Lung Cancer Treatment Using Immune System Wins F.D.A. Approval

(New York Times) Mar 4, 2015 - The first immune-based treatment for lung cancer won approval from the Food and Drug Administration on Wednesday, and it could displace more conventional chemotherapy for certain patients, at least.
read article 

AbbVie to Buy Leukemia Drugmaker Pharmacyclics for $21B

(ABC News/Associated Press) Mar 5, 2015 - AbbVie will spend about $21 billion to buy leukemia drugmaker Pharmacyclics in its first major deal attempt since walking away from a $55 billion takeover of Shire last fall.
read article 

Varmus Stepping Down as Director of NIH’s National Cancer Institute

(NIH) Mar 4, 2015 - Harold Varmus, M.D., who has led the National Cancer Institute (NCI) at the National Institutes of Health (NIH) for nearly five years, announced today that he will step down from his post, effective March 31, 2015.
read press release 

Bristol-Myers Squibb Announces U.S. FDA Approval of an Additional Indication for Opdivo (nivolumab)

(BMS) Mar 4, 2015 - Bristol-Myers Squibb Company today announced an approval of an additional indication for Opdivo (nivolumab) by the U.S. Food and Drug Administration.
read corporate press release 

The FDA Is Forcing Orexigen To Do A Second Safety Study Because Of Contrave Disclosures

(Forbes) Mar 3, 2015 - Orexigen’s failure to keep a lid on a key safety analysis of its obesity drug Contrave led the Food and Drug Administration to force it to do a second study in order to prove that the medicine is safe for the heart.
read article 

Regulators Want Drug Companies to Be Honest About FDA

(TheStreet) Mar 4, 2015 - The Securities and Exchange Commission's top cop wants drug companies to be more transparent with investors about their dealings with the U.S. Food and Drug Administration.
read article 

Bristol's $1 Billion Bavarian Deal May Signal Cancer Vaccine Revival

(Reuters) Mar 4, 2015 - The idea of using vaccines to fight cancer has received a shot in the arm from a $1 billion deal between Bristol-Myers Squibb and Bavarian Nordic.
read article